Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
Herbst, R. S. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med. 383, 1328–1339 (2020).
Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567 (2003).
O’Malley, G. et al. Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer. Cancer Immunol. Res. 6, 1426–1441 (2018).
Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).
Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133.e1117 (2017).
Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710 (2013).
Wu, R. et al. A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. Med. Oncol. 31, 60 (2014).
Wu, D. et al. Five functional polymorphisms of B7/CD28 co-signaling molecules alter susceptibility to colorectal cancer. Cell Immunol. 293, 41–48 (2015).
Wang, W. et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum. Genet. 132, 641–648 (2013).
Sun, T. et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res. 68, 7025–7034 (2008).
Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47, 1304–1315 (2015).
Georgiou, K. et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood 127, 3026–3034 (2016).
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Stein, A. et al. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J. Immunother. Cancer https://doi.org/10.1136/jitc-2021-002844 (2021).
Claass, L. V. et al. PD-L1 amino acid position 88 represents a hotspot for PD-L1 stability with relevance for PD-L1 inhibition. Front. Oncol. 12, 941666 (2022).
Wang, W. et al. A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum. Mutat. 33, 480–484 (2012).
Twa, D. D. et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123, 2062–2065 (2014).
Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268–3277 (2010).
Kataoka, K. et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402–406 (2016). Seminal discovery that structural variants disrupting the 3′-UTR of CD274 lead to constitutive overexpression and immune evasion in multiple cancer types.
Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377–381 (2011).
Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679–690 (2018).
Majzner, R. G. et al. CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering. Blood 136, 53–54 (2020).
Xu, X. et al. CD58 genetic alterations and its contribution to upregulation of PD-L1 and IDO via LYN/CD22/SHP1 axis in DLBCL. Blood 142, 524 (2023).
Miao, B. et al. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell 41, 1817–1828.e1819 (2023). This study, and Ho et al., are key studies demonstrating how co-stimulatory and inhibitory checkpoint axes are coordinately regulated through shared post-translational mechanisms.
Ho, P. et al. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell 41, 1207–1221.e1212 (2023). This study, and Miao et al., are key studies demonstrating how co-stimulatory and inhibitory checkpoint axes are coordinately regulated through shared post-translational mechanisms.
Yan, X. et al. CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv. 6, 5844–5856 (2022).
Wartewig, T. et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552, 121–125 (2017). This study reports a paradigm-shifting discovery that PD1 functions as a tumour suppressor in T cell malignancies, revealing context-dependent roles of immune checkpoints.
Ratner, L., Waldmann, T. A., Janakiram, M. & Brammer, J. E. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N. Engl. J. Med. 378, 1947–1948 (2018).
Gayden, T. et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat. Genet. 50, 1650–1657 (2018).
Yoo, H. Y. et al. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica 101, 757–763 (2016).
Roemer, M. G. M. et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J. Clin. Oncol. 36, 942–950 (2018).
Nakayama, T. et al. Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database. J. Immunother. Cancer https://doi.org/10.1136/jitc-2024-010130 (2024).
Berglund, A. et al. Methylation of immune synapse genes modulates tumor immunogenicity. J. Clin. Invest. 130, 974–980 (2020). This key study demonstrates how epigenetic silencing of immune synapse components creates a coordinated programme of immune suppression in tumours.
Asgarova, A. et al. PD-L1 expression is regulated by both DNA methylation and NF-κB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 7, e1423170 (2018). This key study links EMT to immune checkpoint regulation through coordinated epigenetic and transcriptional mechanisms.
Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463–468 (2021).
Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324–327 (2014).
Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645–661 (2021).
Berghoff, A. S. et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 19, 1460–1468 (2017).
Friedrich, M. et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat. Cancer 2, 723–740 (2021).
Wu, M. J. et al. Mutant IDH inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 12, 812–835 (2022).
Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192–1203 (2018).
Hu, F. F., Liu, C. J., Liu, L. L., Zhang, Q. & Guo, A. Y. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief. Bioinform. https://doi.org/10.1093/bib/bbaa176 (2021).
Peng, Y. et al. A methylation-driven gene panel predicts survival in patients with colon cancer. FEBS Open Bio 11, 2490–2506 (2021).
Cacan, E. Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells. Cell Biol. Int. 41, 328–339 (2017).
Youngblood, B. et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8+ T cells. Immunity 35, 400–412 (2011).
Ghoneim, H. E. et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170, 142–157.e119 (2017). Critical mechanistic study showing how exhausted T cells develop epigenetic programmes that limit the efficacy of PD1 blockade.
Zebley, C. C. et al. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep. 37, 110079 (2021).
Sasidharan Nair, V. et al. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin. Epigenetics 10, 78 (2018).
Sasidharan Nair, V., Toor, S. M., Taha, R. Z., Shaath, H. & Elkord, E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin. Epigenetics 10, 104 (2018).
Liu, J. et al. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene 39, 3939–3951 (2020).
Fan, P. et al. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J. Exp. Clin. Cancer Res. 38, 47 (2019).
Wang, Z. et al. Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. Cell. Mol. Life Sci. 77, 3441–3452 (2020).
Maeda, T., Towatari, M., Kosugi, H. & Saito, H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96, 3847–3856 (2000).
Magner, W. J. et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165, 7017–7024 (2000).
Khan, A. N., Magner, W. J. & Tomasi, T. B. An epigenetically altered tumor cell vaccine. Cancer Immunol. Immunother. 53, 748–754 (2004).
Gialitakis, M. et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by trichostatin A. Nucleic Acids Res. 34, 765–772 (2006).
Kanaseki, T. et al. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J. Immunol. 170, 4980–4985 (2003).
Lu, C. et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J. Natl Cancer Inst. 109, djw283 (2017).
Liu, J. et al. Long noncoding RNA regulating immune escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma. Clin. Transl. Med. 13, e1410 (2023).
Bally, A. P. R. et al. PD-1 expression during acute infection is repressed through an LSD1-Blimp-1 axis. J. Immunol. 204, 449–458 (2020).
Zhang, Y. et al. Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways. Theranostics 14, 7054–7071 (2024).
Xiao, G. et al. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J. Immunother. Cancer 7, 300 (2019).
Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
Chen, S. et al. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J. Exp. Clin. Cancer Res. 37, 3 (2018).
Otsuka, Y. et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol. Immunol. 119, 35–45 (2020).
Xiao, T., Li, S. & Long, X. SMARCAL1: a new target for taming tumor immune evasion. MedComm 5, e730 (2024).
Kim, Y. B., Ahn, J. M., Bae, W. J., Sung, C. O. & Lee, D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int. J. Cancer 145, 916–926 (2019).
Fukumoto, T. et al. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. 79, 5482–5489 (2019).
Liu, M. et al. CHD1L accelated the progression of cutaneous squamous cell carcinoma via promoting PI3K/PD-L1 signaling pathway induced M2 polarization of TAMs. Sci. Rep. 14, 31231 (2024).
Gantzer, J. et al. Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors. Oncologist 27, 501–511 (2022).
Brodeur, M. N. et al. Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity. Sci. Adv. 10, eadk4851 (2024).
Liu, Y. et al. BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression. J. Neurooncol 171, 669–679 (2025).
Zhao, J. et al. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int. J. Biochem. Cell Biol. 108, 84–91 (2019).
Zhong, M. et al. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. Cell Death Dis. 13, 671 (2022).
Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227–231 (2016). Pivotal study linking the master oncogene MYC to immune checkpoint regulation, demonstrating direct transcriptional control of immune evasion pathways integrated with oncogenic signalling.
Romberg, N. et al. Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J. Allergy Clin. Immunol. 131, 1691–1693 (2013).
Song, T. L. et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 132, 1146–1158 (2018).
Marzec, M. et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl Acad. Sci. USA 105, 20852–20857 (2008).
Chen, N. et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J. Thorac. Oncol. 10, 910–923 (2015).
Feng, D. et al. BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene 38, 6752–6766 (2019).
Sumimoto, H., Takano, A., Teramoto, K. & Daigo, Y. RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers. PLoS ONE 11, e0166626 (2016).
Jiang, J. et al. Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma. Cancer Commun. 44, 1350–1373 (2024).
Nishi, K. et al. Mutant KRAS promotes NKG2D+ T cell infiltration and CD155 dependent immune evasion. Anticancer. Res. 40, 4663–4674 (2020).
Xu, C. et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25, 590–604 (2014).
Abdelhamed, S., Ogura, K., Yokoyama, S., Saiki, I. & Hayakawa, Y. AKT-STAT3 pathway as a downstream target of EGFR signaling to regulate PD-L1 expression on NSCLC cells. J. Cancer 7, 1579–1586 (2016).
Du, L. et al. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J. Exp. Med. https://doi.org/10.1084/jem.20191115 (2020).
Li, Y. et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci. Adv. 8, eadd6403 (2022).
Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871–881 (2006).
Matsuzaki, J. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107, 7875–7880 (2010).
Kumar, B. et al. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Sci. Transl. Med. 16, eadp0004 (2024).
Brown, R. D. et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98, 2992–2998 (2001).
Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).
Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024).
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e1512 (2016).
Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4, 43–61 (2023).
Ye, Z. H. et al. Regulation of CD47 expression by interferon-gamma in cancer cells. Transl. Oncol. 14, 101162 (2021).
Jing, Z. L. et al. Interferon-gamma in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells. Sci. Rep. 14, 6053 (2024).
Rosenbaum, S. R. et al. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 37, 110085 (2021).
Wang, X. et al. Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol. Lett. 184, 7–14 (2017).
Betancur, P. A. et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat. Commun. 8, 14802 (2017).
Lamano, J. B. et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin. Cancer Res. 25, 3643–3657 (2019).
Yao, Y. et al. B7-H4(B7x)-mediated cross-talk between glioma-initiating cells and macrophages via the IL6/JAK/STAT3 pathway lead to poor prognosis in glioma patients. Clin. Cancer Res. 22, 2778–2790 (2016).
Chen, J. et al. Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. Oncoimmunology 8, e1652540 (2019).
Zheng, Y. et al. Tumor-activated neutrophils promote lung cancer progression through the IL-8/PD-L1 pathway. Curr. Cancer Drug Targets 25, 294–305 (2025).
Sun, L. et al. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell Death Dis. 9, 928 (2018).
Apostolova, P. & Pearce, E. L. Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. Trends Immunol. 43, 969–977 (2022).
Deng, H. et al. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J. Immunother. Cancer 9, e002305 (2021).
Roux, C. et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc. Natl Acad. Sci. USA 116, 4326–4335 (2019).
Chung, C. H. et al. Ferroptosis signature shapes the immune profiles to enhance the response to immune checkpoint inhibitors in head and neck cancer. Adv. Sci. 10, e2204514 (2023).
Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).
Platten, M., Nollen, E. A. A., Rohrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379–401 (2019).
Liu, Y. et al. Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation. Cancer Cell 33, 480–494.e487 (2018).
Kober, C. et al. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. J. Immunother. Cancer https://doi.org/10.1136/jitc-2023-007495 (2023).
Kenison, J. E. et al. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation. Proc. Natl Acad. Sci. USA 118, e2012692118 (2021).
Barsoum, I. B., Smallwood, C. A., Siemens, D. R. & Graham, C. H. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665–674 (2014).
Samanta, D. et al. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl Acad. Sci. USA 115, E1239–E1248 (2018).
Bailey, C. M. et al. Targeting HIF-1alpha abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J. Clin. Invest. https://doi.org/10.1172/JCI150846 (2022).
Jeon, Y. K. et al. Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1alpha and promotes cancer cell proliferation. Biochem. Biophys. Res. Commun. 459, 277–283 (2015).
Zhang, H. et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc. Natl Acad. Sci. USA 112, E6215–E6223 (2015).
Deng, J. et al. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol. Res. 7, 1079–1090 (2019).
Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415 (2008).
Marasco, L. E. & Kornblihtt, A. R. The physiology of alternative splicing. Nat. Rev. Mol. Cell Biol. 24, 242–254 (2023).
Baralle, F. E. & Giudice, J. Alternative splicing as a regulator of development and tissue identity. Nat. Rev. Mol. Cell Biol. 18, 437–451 (2017).
Mahoney, K. M. et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol. Immunother. 68, 421–432 (2019).
Charifa, A. et al. Expression of alternatively spliced PD-L1 RNA with skipping of transmembrane domain. J. Clin. Oncol. 42, e14596 (2024).
Gong, B. et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J. Exp. Med. 216, 982–1000 (2019).
Szeles, A. et al. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Cancer Immunol. Immunother. 72, 1061–1073 (2023).
Zhou, J. et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol. Res. 5, 480–492 (2017).
Laurent, S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J. Transl. Med. 11, 108 (2013).
Ward, F. J. et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur. J. Immunol. 43, 1274–1285 (2013).
Oaks, M. K. et al. A native soluble form of CTLA-4. Cell Immunol. 201, 144–153 (2000).
Sorensen, S. F., Demuth, C., Weber, B., Sorensen, B. S. & Meldgaard, P. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer 100, 77–84 (2016).
Labiano, S. et al. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. Oncoimmunology 5, e1062967 (2016).
Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083–1099.e1086 (2017). This study uncovers a post-transcriptional mechanism of immune evasion, showing that oncogenic RAS–MAPK signalling increases the stability of PDL1 mRNA via inhibition of mRNA decay, thereby elevating checkpoint protein levels and promoting tumour immunoresistance.
Ansa-Addo, E. A. et al. RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity. Sci. Adv. 6, eaaz3865 (2020).
Liu, Y., Li, X., Zhang, H., Zhang, M. & Wei, Y. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene 40, 2230–2242 (2021).
Ni, Z. et al. JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res. 82, 1789–1802 (2022).
Qiu, X. et al. m6A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 81, 4778–4793 (2021).
Wang, X. et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 161, 1388–1399 (2015).
Li, T. et al. Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts. Gut 72, 501–511 (2023).
Chen, R. et al. N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer. iScience 27, 108956 (2024).
Cortez, M. A. et al. PDL1 regulation by p53 via miR-34. J. Natl Cancer Inst. 108, djv303 (2016).
Chen, L. et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 5, 5241 (2014).
Leopizzi, M. et al. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma. Blood 143, 429–443 (2024).
Wang, Q. M., Lian, G. Y., Song, Y., Huang, Y. F. & Gong, Y. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 231, 116335 (2019).
Mekky, R. Y., Ragab, M. F., Manie, T., Attia, A. A. & Youness, R. A. MALAT-1: immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer. Transl. Oncol. 31, 101653 (2023).
Park, E. G., Pyo, S. J., Cui, Y., Yoon, S. H. & Nam, J. W. Tumor immune microenvironment lncRNAs. Brief. Bioinform. https://doi.org/10.1093/bib/bbab504 (2022).
Yan, K. et al. Repression of lncRNA NEAT1 enhances the antitumor activity of CD8+ T cells against hepatocellular carcinoma via regulating miR-155/Tim-3. Int. J. Biochem. Cell Biol. 110, 1–8 (2019).
Gao, Y. et al. LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma. Mol. Immunol. 117, 20–28 (2020).
Wang, J. et al. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis. 11, 32 (2020).
Cerezo, M. et al. Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma. Nat. Med. 24, 1877–1886 (2024).
Zhao, S. et al. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells. J. Immunother. Cancer https://doi.org/10.1136/jitc-2022-004875 (2022).
Xu, Y. et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat. Med. 25, 301–311 (2019).
Cao, Y., Ye, Q., Ma, M. & She, Q. B. Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors. Cell Rep. 42, 112764 (2023).
Manske, F. et al. The new uORFdb: integrating literature, sequence, and variation data in a central hub for uORF research. Nucleic Acids Res. 51, D328–D336 (2023).
Thomas-Jardin, S. et al. The integrated stress response pathway coordinates translational control of multiple immune checkpoints in lung cancer. Cancer Res. 85, 2574–2590 (2025).
Suresh, S. et al. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat. Cancer 1, 533–545 (2020).
Franchini, D. M. et al. Microtubule-driven stress granule dynamics regulate inhibitory immune checkpoint expression in T cells. Cell Rep. 26, 94–107.e107 (2019).
Dai, X. et al. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer. Cell Commun. Signal. 22, 168 (2024).
Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925–939 (2016). This paper, possibly for the first time, links proteostatic regulation of PDL1 to immune evasion by demonstrating that the COP9 signalosome subunit CSN5 acts as a deubiquitinase for PDL1, preventing PDL1 degradation in cancer cells.
Meng, X. et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature 564, 130–135 (2018). This discovery shows that T cells actively regulate their own checkpoint expression: the E3 ubiquitin ligase FBXO38 targets PD1 for degradation in activated T cells, and loss of FBXO38 leads to elevated PD1 and impaired T cell immunity.
Du, L. et al. EGFR-induced and c-Src-mediated CD47 phosphorylation inhibits TRIM21-dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion. Adv. Sci. 10, e2206380 (2023).
Liu, J. et al. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. J. Immunother. Cancer https://doi.org/10.1136/jitc-2022-005116 (2022).
Li, C. W. et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187–201.e110 (2018).
Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).
Chan, L. C. et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J. Clin. Invest. 129, 3324–3338 (2019).
Song, X. et al. Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov. 10, 1872–1893 (2020).
Okada, M. et al. Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep. 20, 1017–1028 (2017).
Shi, M., Nan, X. R. & Liu, B. Q. The multifaceted role of FUT8 in tumorigenesis: from pathways to potential clinical applications. Int. J. Mol. Sci. https://doi.org/10.3390/ijms25021068 (2024).
Yang, Y. et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 29, 83–86 (2019).
Yao, H. et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat. Biomed. Eng. 3, 306–317 (2019).
Zhang, Z. et al. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci. Immunol. 9, eadp7302 (2024).
Zitti, B. et al. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Sci. Rep. 7, 10445 (2017).
Gao, Y. et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat. Cell Biol. 22, 1064–1075 (2020).
Nihira, N. T. et al. Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage. EMBO Rep. 26, 635–655 (2025).
Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101–105 (2017).
Mezzadra, R. et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106–110 (2017).
Benicky, J. et al. PD-L1 glycosylation and its impact on binding to clinical antibodies. J. Proteome Res. 20, 485–497 (2021).
Huang, C. et al. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Sci. Adv. 9, eade4186 (2023).
Dong, Y. et al. VSTM2A reverses immunosuppression in colorectal cancer by antagonizing the PD-L1/PD-1 interaction. Mol. Ther. 32, 4045–4057 (2024).
Sugiura, D. et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 364, 558–566 (2019).
Kennedy, A. et al. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80. EMBO J. 42, e111556 (2023).
Zhao, Y. et al. PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity 51, 1059–1073.e1059 (2019).
Zhang, Y. et al. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc. Natl Acad. Sci. USA 120, e2205085120 (2023).
Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34, 2690–2697 (2016).
Goodman, A. M. et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 4, 1237–1244 (2018).
Gupta, S. et al. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Hum. Pathol. 88, 87–91 (2019).
Egg, D. et al. Increased risk for malignancies in 131 affected CTLA4 mutation carriers. Front. Immunol. 9, 2012 (2018).
Kelly, A. D. et al. Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. J. Immunother. Cancer https://doi.org/10.1136/jitc-2021-003550 (2021).
Niebel, D. et al. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clin. Epigenetics 14, 50 (2022).
Zhang, C. et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. Oncoimmunology 7, e1461304 (2018).
Klumper, N. et al. PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. Oncoimmunology 12, 2267744 (2023).
Xiao, T. & Zhang, Y. E. Targeting epigenetic regulators to boost T cell immunotherapy against cancer. Cell Biosci. https://doi.org/10.1186/s13578-026-01533-y (2026).
Saleh, R., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Role of epigenetic modifications in inhibitory immune checkpoints in cancer development and progression. Front. Immunol. 11, 1469 (2020).
de Vos, L. et al. The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics 15, 1195–1212 (2020).
Zhang, R., Wu, H. X., Xu, M. & Xie, X. KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors. Biomark Res. 8, 71 (2020).
Zhang, P. & Huang, Y. Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers. J. Hematol. Oncol. 14, 39 (2021).
Wang, D. X. et al. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Mol. Cancer 23, 15 (2024).
Gomez, S., Tabernacki, T., Kobyra, J., Roberts, P. & Chiappinelli, K. B. Combining epigenetic and immune therapy to overcome cancer resistance. Semin. Cancer Biol. 65, 99–113 (2020).
Starzer, A. M. et al. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J. Immunother. Cancer https://doi.org/10.1136/jitc-2021-003420 (2022).
Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017). This study defines a pretreatment ‘T cell-inflamed’ gene expression signature (dominated by IFNγ-stimulated genes) in tumours that correlates with positive responses to PD1 blockade, establishing a foundation for predictive biomarkers of checkpoint inhibitor efficacy and patient selection in immunotherapy.
Higgs, B. W. et al. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin. Cancer Res. 24, 3857–3866 (2018).
Zhang, Z. et al. Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. EBioMedicine 83, 104207 (2022).
Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994–1004 (2018).
Rodig, N. et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33, 3117–3126 (2003).
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
Patel, S. A. et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin. Cancer Res. 29, 30–39 (2023).
Briere, D. M. et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol. Cancer Ther. 20, 975–985 (2021).
Mugarza, E. et al. Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci. Adv. 8, eabm8780 (2022).
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).
Jänne, P. A. et al. First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. J. Clin. Oncol. 43 (suppl. 16), Abstr. 8500 (2025).
Zhang, N. et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int. J. Oncol. 49, 1360–1368 (2016).
Bugide, S., Reddy, D. S., Malvi, P., Gupta, R. & Wajapeyee, N. ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience 27, 109800 (2024).
Du, P., Hu, T., An, Z., Li, P. & Liu, L. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Cancer Sci. 111, 1887–1898 (2020).
Creelan, B. C. et al. A phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. Br. J. Cancer 124, 383–390 (2021).
Yang, J. C. et al. Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation. J. Thorac. Oncol. 14, 553–559 (2019).
Solomon, B. J. et al. Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN Lung 101 trial. JTO Clin. Res. Rep. 5, 100685 (2024).
Kim, D. W. et al. Brief report: Safety and antitumor activity of alectinib plus atezolizumab from a phase 1b study in advanced ALK-positive NSCLC. JTO Clin. Res. Rep. 3, 100367 (2022).
Spigel, D. R. et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation – positive advanced non-small cell lung cancer (CheckMate 370). J. Thorac. Oncol. 13, 682–688 (2018).
Zhang, W. et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J. Immunother. Cancer https://doi.org/10.1136/jitc-2019-000285 (2020).
Luo, F. et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J. Immunother. Cancer 7, 245 (2019).
Kawazoe, A. et al. Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial). Clin. Cancer Res. 26, 5887–5894 (2020).
Jing, X. et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Exp. Cell Res. 392, 112034 (2020).
Zhu, H. et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 16, 2829–2837 (2016).
Hogg, S. J. et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 18, 2162–2174 (2017).
Wang, Z. Q. et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduct. Target. Ther. 8, 420 (2023).
Tseng, H. Y. et al. BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment. Pigment Cell Melanoma Res. 37, 744–751 (2024).
To, K. K. W., Xing, E., Larue, R. C. & Li, P. K. BET bromodomain inhibitors: novel design strategies and therapeutic applications. Molecules 28, 3043 (2023).
Chuntova, P. et al. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. J. Immunother. Cancer https://doi.org/10.1136/jitc-2022-004644 (2022).
Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425–1437 (2017).
Kadiyala, P. et al. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J. Clin. Invest. https://doi.org/10.1172/JCI139542 (2021).
Nguyen, M. K. et al. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. Oncologist 30, oyaf362 (2025).
Nguyen, M. K. et al. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. Oncologist https://doi.org/10.1093/oncolo/oyaf362 (2025).
Makowska, A. et al. Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunol. Immunother. 70, 323–336 (2021).
Makowska, A. et al. Radiotherapy combined with PD-1 inhibition increases NK cell cytotoxicity towards Nasopharyngeal carcinoma cells. Cells 10, 2458 (2021).
Wang, Z. et al. ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. J. Immunother. Cancer https://doi.org/10.1136/jitc-2020-001758 (2021).
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Sow, H. S., Ren, J., Camps, M., Ossendorp, F. & Ten Dijke, P. Combined inhibition of TGF-beta signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells 8, 320 (2019).
Principe, D. R. et al. TGFbeta blockade augments PD-1 inhibition to promote T-cell-mediated regression of pancreatic cancer. Mol. Cancer Ther. 18, 613–620 (2019).
Kim, T. W. et al. 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer. Ann. Oncol. 34, S443 (2023).
Yi, L. et al. Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial. Signal Transduct. Target. Ther. 9, 347 (2024).
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
Pelly, V. S. et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 11, 2602–2619 (2021).
Lacher, S. B. et al. PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature 629, 417–425 (2024).
Morotti, M. et al. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 629, 426–434 (2024).
Elewaut, A. et al. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature 637, 716–725 (2025).
Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341–1358.e1311 (2023).
Cecil, D. L. et al. COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of type I tumor-infiltrating lymphocytes. Cancer Prev. Res. 15, 225–231 (2022).
Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T. & Kusmartsev, S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl Acad. Sci. USA 114, 1117–1122 (2017).
Wei, J. et al. The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas. Cancer Prev. Res. 15, 285–296 (2022).
Yun, S. J. et al. Regulation of TIM-3 expression in a human T cell line by tumor-conditioned media and cyclic AMP-dependent signaling. Mol. Immunol. 105, 224–232 (2019).
Kanai, O. et al. Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer. Thorac. Cancer 12, 949–957 (2021).
Wang, D. Y. et al. The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma. Oncologist 25, e602–e605 (2020).
Wang, S. J. et al. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. J. Immunother. Cancer https://doi.org/10.1136/jitc-2020-000889 (2020).
Quandt, Z. et al. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Rep. 2, 46 (2024).
Wu, Z. et al. PD-1 blockade combined with COX inhibitor in patients with MSI-H/dMMR or high TMB, advanced or metastatic colorectal cancer (PCOX study). J. Clin. Oncol. 38, 111 (2020).
Hu, H. et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 38–48 (2022).
Sebastian, N. T. et al. The association of improved overall survival with NSAIDs in non-small cell lung cancer patients rReceiving immune checkpoint inhibitors. Clin. Lung Cancer 24, 287–294 (2023).
Kumar, P. et al. Does concurrent COX inhibition and immune checkpoint blockade improve clinical outcomes in patients with metastatic renal cell carcinoma (mRCC)? J. Clin. Oncol. 40, 354 (2022).
Hu, Z. P2RY2 is a purinergic immune checkpoint linking extracellular ATP to immune evasion and adaptive resistance to immunotherapy. Preprint at bioRxiv https://doi.org/10.1101/2025.10.09.681049 (2025).
Falcinelli, M. et al. Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer. Brain Behav. Immun. 110, 1–12 (2023).
Qiao, G. et al. Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment. Cancer Immunol. Res. 9, 651–664 (2021).
Gandhi, S. et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin. Cancer Res. 27, 87–95 (2021).
Kim, K. H. PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. Cell Mol. Immunol. 18, 385–397 (2021).
Geng, R. et al. Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients. Front/Immunol. 14, 1125876 (2023).
Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006). Landmark safety study that fundamentally changed approaches to immune checkpoint modulation, demonstrating the crucial importance of understanding co-stimulatory checkpoint biology.
Claus, C., Ferrara-Koller, C. & Klein, C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs 15, 2167189 (2023).
Kitajima, S. et al. Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells. Oncotarget 9, 19123–19135 (2018).
Wang, L. X. et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS ONE 8, e62924 (2013).
Bae, J. et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia 32, 1932–1947 (2018).
Li, X. et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene 40, 1836–1850 (2021).
Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4, 2067–2079 (2013).
Godfrey, J. et al. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma. Haematologica 109, 533–542 (2024).
Borcoman, E. et al. Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial. Nat. Cancer 6, 1370–1383 (2025).
[No authors listed]. FDA approves anti-LAG3 checkpoint. Nat. Biotechnol. 40, 625 (2022).
Huard, B., Prigent, P., Tournier, M., Bruniquel, D. & Triebel, F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 25, 2718–2721 (1995).
Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23, 757–767 (2022).
Li, N. et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 26, 494–504 (2007).
Ghazavi, F. et al. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. Haematologica 100, 1311–1319 (2015).
Salzer, E. et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 98, 473–478 (2013).
Kishore, R., Gupta, A., Gupta, A. K. & Kabra, S. K. Novel mutation in the CD27 gene in a patient presenting with hypogammaglobulinemia, bronchiectasis and EBV-driven lymphoproliferative disease. BMJ Case Rep. https://doi.org/10.1136/bcr-2019-233482 (2020).
Alkhairy, O. K. et al. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. J. Allergy Clin. Immunol. 136, 703–712.e710 (2015).
Bouska, A. et al. Integrative genomic and transcriptomic analysis reveals targetable vulnerabilities in angioimmunoblastic T-cell lymphoma. Am. J. Hematol. 100, 1486–1501 (2025).
Rohr, J. et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 30, 1062–1070 (2016).
Gmyrek, G. B., Pingel, J., Choi, J. & Green, J. M. Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. Cell Immunol. 319, 28–34 (2017).
Sakamoto, Y. et al. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma. Br. J. Haematol. 192, 281–291 (2021).
Vallois, D. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128, 1490–1502 (2016).
Dimitrakopoulos, F. D. et al. Genetic variations of CD40 and LTbetaR genes are associated with increased susceptibility and clinical outcome of non-small-cell carcinoma patients. Front. Oncol. 11, 721577 (2021).
Skibola, C. F. et al. A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 111, 4348–4354 (2008).
Qi, C. J. et al. A novel mutation in CD40 and its functional characterization. Hum. Mutat. 30, 985–994 (2009).
Wang, H. L. et al. A novel CD58 mutation-related signature predicts prognosis risk in diffuse large B-cell lymphoma patients. Cancer Res. Treat. https://doi.org/10.4143/crt.2024.1143 (2025).
Xu, X. et al. CD58 alterations govern antitumor immune responses by inducing PDL1 and IDO in diffuse large B-cell lymphoma. Cancer Res. 84, 2123–2140 (2024).
Xing, L., Wang, H., Liu, D., He, Q. & Li, Z. Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test. Front. Oncol. 12, 1079890 (2022).
Abolhassani, H. et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J. Exp. Med. 214, 91–106 (2017).
Ye, X. et al. Genomic characterization of lymphomas in patients with inborn errors of immunity. Blood Adv. 6, 5403–5414 (2022).
Izawa, K. et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J. Exp. Med. 214, 73–89 (2017).
Scholtysik, R. et al. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. Int. J. Cancer 131, E830–E835 (2012).
Koh, J. et al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 5, 3919–3930 (2021).
Zhang, Y. et al. A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling. Front. Oncol. 12, 870676 (2022).
Polprasert, C. et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv. 3, 588–595 (2019).
Schepp, J. et al. 14 Years after discovery: clinical follow-up on 15 patients with inducible co-stimulator deficiency. Front. Immunol. 8, 964 (2017).
Yang, P. et al. A functional variant at miR-24 binding site in B7-H2 alters susceptibility to gastric cancer in a Chinese Han population. Mol. Immunol. 56, 98–103 (2013).
Park, J. et al. Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood 138, 1225–1236 (2021).
Polcaro, G. et al. rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy. J. Immunother. Cancer https://doi.org/10.1136/jitc-2025-012207 (2025).
Wu, J. et al. Hi-C allows genome-wide characterization of enhancer-driven oncogene rearrangements in formalin-fixed lymphoid cancer biopsies. Blood 144, 4973 (2024).
Twa, D. D. et al. Recurrent genomic rearrangements in primary testicular lymphoma. J. Pathol. 236, 136–141 (2015).
Chapuy, B. et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127, 869–881 (2016).
Lee, J. H. et al. Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome. Sci. Rep. 11, 1794 (2021).
Matsuo, T., Iguchi-Manaka, A., Shibuya, A. & Shibuya, K. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT. Cancer Sci. 113, 4001–4004 (2022).
Byun, M. et al. Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J. Exp. Med. 210, 1743–1759 (2013).
Somekh, I. et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood 134, 1510–1516 (2019).
Shen, K. et al. CD137 deficiency because of two novel biallelic TNFRSF9 mutations in a patient presenting with severe EBV-associated lymphoproliferative disease. Clin. Transl. Immunol. 12, e1448 (2023).
Alosaimi, M. F. et al. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. J. Allergy Clin. Immunol. 144, 574–583.e575 (2019).
Zhao, P. et al. Clinical and functional characterization of a novel TNFRSF9 variant causing immune dysregulation with predisposition to EBV-driven lymphomagenesis. Front. Immunol. 16, 1605221 (2025).
Salloum, D. Abstract PR03: HVEM (TNFRSF14) tumor suppressor in immune therapies of follicular lymphoma. Cancer Immunology Res. 4, PR03 (2016).
Fournier, B. et al. Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors. J. Exp. Med. https://doi.org/10.1084/jem.20211682 (2022).
Liu, Y., Dai, Y. & Wang, L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell 44, 24–49 (2026).
Koh, J. et al. Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and its immune microenvironment according to PD-L1 expression. Cancer Immunol. Res. 12, 1753–1764 (2024).
Madsen, T. D. et al. Myeloid states predict fate of premalignant lesions. Preprint at bioRxiv https://doi.org/10.1101/2025.11.02.686127 (2026).
Lee, M. Y. et al. Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma. J. Immunother. Cancer https://doi.org/10.1136/jitc-2025-014067 (2026).
Takano, Y. et al. Spatially resolved gene expression profiling of tumor microenvironment reveals key steps of lung adenocarcinoma development. Nat. Commun. 15, 10637 (2024).
Mu, M., Melms, J. C., Ho, P. & Izar, B. Large-scale CRISPR-Cas9 screens to define regulators of immune checkpoints. Methods Cell Biol. 202, 117–132 (2026).
Papalexi, E. et al. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens. Nat. Genet. 53, 322–331 (2021).
Zhou, P. et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature 624, 154–163 (2023).
Vanguri, R. S. et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat. Cancer 3, 1151–1164 (2022).
Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018).
Captier, N. et al. Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer. Nat. Commun. 16, 614 (2025).
Anagnostou, V. et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 79, 1214–1225 (2019).
Anagnostou, V. et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat. Med. 29, 2559–2569 (2023).
Wang, B. et al. Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma. Nat. Commun. 16, 8161 (2025).